Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 10;13(9):2277.
doi: 10.3390/cancers13092277.

Neuroendocrine Factors in Melanoma Pathogenesis

Cristian Scheau  1 , Carmen Draghici  2 , Mihaela Adriana Ilie  2 , Mihai Lupu  2 , Iulia Solomon  2 , Mircea Tampa  3 , Simona Roxana Georgescu  3 , Ana Caruntu  4   5 , Carolina Constantin  6   7 , Monica Neagu  6   7   8 , Constantin Caruntu  1   9
Affiliations
Review

Neuroendocrine Factors in Melanoma Pathogenesis

Cristian Scheau et al. Cancers (Basel). .

Abstract

Melanoma is one of the most aggressive skin cancers with a sharp rise in incidence in the last decades, especially in young people. Recognized as a significant public health issue, melanoma is studied with increasing interest as new discoveries in molecular signaling and receptor modulation unlock innovative treatment options. Stress exposure is recognized as an important component in the immune-inflammatory interplay that can alter the progression of melanoma by regulating the release of neuroendocrine factors. Various neurotransmitters, such as catecholamines, glutamate, serotonin, or cannabinoids have also been assessed in experimental studies for their involvement in the biology of melanoma. Alpha-MSH and other neurohormones, as well as neuropeptides including substance P, CGRP, enkephalin, beta-endorphin, and even cellular and molecular agents (mast cells and nitric oxide, respectively), have all been implicated as potential factors in the development, growth, invasion, and dissemination of melanoma in a variety of in vitro and in vivo studies. In this review, we provide an overview of current evidence regarding the intricate effects of neuroendocrine factors in melanoma, including data reported in recent clinical trials, exploring the mechanisms involved, signaling pathways, and the recorded range of effects.

Keywords: melanoma; neurohormones; neuropeptides; neurotransmitters; stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Neuroendocrine factors produced in different compartments of the skin and their most relevant effects on melanoma cells via specific receptors.
Figure 2
Figure 2
Neuroendocrine factors released by melanoma cells and their effects on the tumor microenvironment.
Figure 3
Figure 3
Role of β-adrenergic modulatory mechanisms in tumor development and progression. Release of catecholamines in the tumor tissue associated with activation of sympathoadrenal system, stimulates β-adrenergic receptors on melanoma and tumor microenvironment cells. In tumor cells it further induces an increase of cAMP formation which, in its turn, activates multiple intracellular signaling pathways, such as GATA1, CREB and ATF, initiating protumorigenic mechanisms. Adrenergic stimulation of tumor infiltrating immune cells (TIICs) increases the production of proinflammatory cytokines and matrix metalloproteinases (MMPs), also favoring tumor growth, invasion and metastasis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nikolaou V., Stratigos A.J. Emerging trends in the epidemiology of melanoma. Br. J. Derm. 2014;170:11–19. doi: 10.1111/bjd.12492. - DOI - PubMed
    1. Liu Y., Sheikh M.S. Melanoma: Molecular Pathogenesis and Therapeutic Management. Mol. Cell. Pharmacol. 2014;6:228. - PMC - PubMed
    1. Schadendorf D., van Akkooi A.C.J., Berking C., Griewank K.G., Gutzmer R., Hauschild A., Stang A., Roesch A., Ugurel S. Melanoma. Lancet. 2018;392:971–984. doi: 10.1016/S0140-6736(18)31559-9. - DOI - PubMed
    1. Feigelson H.S., Powers J.D., Kumar M., Carroll N.M., Pathy A., Ritzwoller D.P. Melanoma incidence, recurrence, and mortality in an integrated healthcare system: A retrospective cohort study. Cancer Med. 2019;8:4508–4516. doi: 10.1002/cam4.2252. - DOI - PMC - PubMed
    1. Tsao H., Chin L., Garraway L.A., Fisher D.E. Melanoma: From mutations to medicine. Genes Dev. 2012;26:1131–1155. doi: 10.1101/gad.191999.112. - DOI - PMC - PubMed